surpass cvot tirzepatide results Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular Outcomes in Type 2 Diabetes

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

29.05

★★★★☆4.8 (126)

Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and

23.28

★★★★★4.9 (98)

Should Diabetes Management be More Adipose-Centric?

20.10

★★★★★5.0 (157)

Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study

21.80

★★★★★4.7 (84)

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme - Pedersen

25.07

★★★★★4.9 (203)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

27.09

★★★★★5.0 (176)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

29.85

★★★★★4.8 (132)